About
ISOThrive is a clinical stage biotech company developing novel digestion-resistant carbohydrates as microbiome therapeutics to treat chronic diseases caused by microbiome dysbiosis, with a lead asset currently in phase 2 trials.
Explore ISOThrive's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.